Sihuan's Generic Drug Nalmefene Hydrochloride Receives Approval for Pharmaceutical Registration from State Food and Drug

     Sihuan's Generic Drug Nalmefene Hydrochloride Receives Approval for
     Pharmaceutical Registration from State Food and Drug Administration

Drug set for launch in the first quarter of this year

Poised to strengthen Sihuan's development in the central nervous system drugs

PR Newswire

HONG KONG, Jan. 16, 2013

HONG KONG, Jan. 16, 2013 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group
Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading
pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug
franchise in China's prescription market, announced that the new Category 3.1
drug, the Nalmefene Hydrochloride Injection ("Nalmefene Hydrochloride"),
received a new drug certificate (H20120078) and approval for production
(2012S00818) from the State Food and Drug Administration. Nalmefene
Hydrochloride is yet another generic drug for which the Company has received
approval for production following the Roxatidine Acetate Hydrochloridefor
Injection. It will be manufactured by Beijing Sihuan Pharmaceutical Co., Ltd.,
a wholly-owned manufacturing subsidiary of the Company.

Nalmefene hydrochloride is a next generation opioid (opium) receptor inhibitor
following Naloxone and Naltrexone. The injection formulation of Naloxone
hydrochloride was invented by Ohmeda Pharmaceuticals and was approved by the
US Food and Drug Administration (FDA) in 1995. The clinical uses of Nalmefene
hydrochloride include anti-shock, neuroprotection, treatment for acute
morphine poisoning, drug relapse prevention, recovery from the after-effects
of anesthesia such as respiratory and nerve center depression and the
treatment of unconsciousness persons. The drug is also effective for treating
heart failure and spinal cord injuries, for cerebral protection, etc.
Multi-centre, randomized, blind, and positive-controlled clinical research of
this new drug were performed by the Peking University First Hospital, the
First Affiliated Hospital of China Medical University, Xijing Hospital (The
First Affiliated Hospital of the Fourth Military Medical College) and Qingdao
Municipal Hospital.

Compared to Naloxone, Nalmefene demonstrates longer curative effects and fewer
adverse reactions. With its high bioavailability, biological activities and
biofilm penetration ability, it helps to regulate respiration, circulation,
digestion, and the endocrine and nervous systems. It is becoming a substitute
for Naloxone, and has been included in Part B of the National Medicine
Catalogue. At present, the size of the Nalmefene hydrochloride market in China
is approximately RMB1 billion. As a substitution for Naloxone hydrochloride,
Nalmefene hydrochloride has enormous market potential.

Diseases of the central nervous system (CNS) are common in China, which has an
immense patient base. Due to the rapid pace of modern life, accelerated
urbanisation and mental stress, the demand for CNS medicines has seen rapid
growth in recent years given the rising number of patients. According to IMS,
the size of the CNS drug market now exceeds RMB 23 billion. With the CNS drug
market expected to reach RMB 100 billion in 2020, the Group sees great
potential and strong growth prospects in the market.

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, "Nalmefene
Hydrochloride has shown unique characteristics for treatment and high clinical
value. Its market demonstrates great potential to expand. Leveraging Sihuan
Pharmaceutical's strong marketing capabilities and extensive sales and
distribution network, we believe that our market share for Nalmefene
Hydrochloride will see rapid growth, which will strengthen our position in
drugs for the treatment of major diseases of the central nervous system. This
will in turn enhance the continuous development and growth of Sihuan
Pharmaceutical and create value for the shareholders and the Company."

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading
pharmaceutical company and the largest cardio-cerebral vascular drug franchise
in China's prescription drug market by market share. The success of the Group
can be attributed to its differentiated and proven sales and marketing model,
diversified portfolio of market leading drugs, extensive nationwide
distribution network, and strong research and development capabilities. Sihuan
Pharmaceutical major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao, GM1
and Oudimei are widely used in the treatment of various cardio-cerebral
vascular diseases.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.

Contact: Hill+Knowlton Strategies Asia, Angela Kung, +852-2894-6374 /
6017-7030,; or Ada Ho, +852-2894-6290 /
Press spacebar to pause and continue. Press esc to stop.